- Public Comps
- Biomerica
Biomerica Valuation Multiples
Discover revenue and EBITDA valuation multiples for Biomerica and similar public comparables like Bluejay Diagnostics, Centogene, Virax Biolabs Group, NRGene and more.
Biomerica Overview
About Biomerica
Biomerica Inc is engaged in the development, manufacturing, and marketing of medical diagnostic products designed for the early detection and monitoring of chronic diseases and medical conditions. The company focuses on products for gastrointestinal diseases, food intolerances, diabetes, and certain esoteric tests. The Company manages its operations as a single operating and reportable segment, which focus on the development, manufacture, marketing, and sale of diagnostic products. The majority of the company's revenue is earned from the Asia, and also has its presence in Europe, North America, Middle East and South America.
Founded
1971
HQ

Employees
54
Website
Financials (FY)
EV
$4M
Valuation Multiples
Start free trialBiomerica Financials
Biomerica reported last fiscal year revenue of $5M and negative EBITDA of ($5M).
In the same fiscal year, Biomerica generated $498K in gross profit, ($5M) in EBITDA losses, and had net loss of ($5M).
Biomerica P&L
In the most recent fiscal year, Biomerica reported revenue of $5M and EBITDA of ($5M).
Biomerica is unprofitable as of last fiscal year, with gross margin of 9%, EBITDA margin of (89%), and net margin of (94%).
Financial data powered by Morningstar, Inc.
Biomerica Stock Performance
Biomerica has current market cap of $5M, and enterprise value of $4M.
Market Cap Evolution
Biomerica's stock price is $1.52.
Biomerica has an EPS (earnings per share) of $-1.61.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $4M | $5M | -1.9% | - | - | - | $-1.61 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialBiomerica Valuation Multiples
Biomerica trades at 0.7x EV/Revenue multiple, and (0.8x) EV/EBITDA.
Biomerica Financial Valuation Multiples
As of August 21, 2026, Biomerica has market cap of $5M and EV of $4M.
Biomerica has a P/E ratio of (0.9x).
Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Biomerica Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.


Biomerica Margins & Growth Rates
In the most recent fiscal year, Biomerica reported gross margin of 9%, EBITDA margin of (89%), and net margin of (94%).
Biomerica Margins
Biomerica Growth Rates
Data powered by FactSet, Inc. and Morningstar, Inc.
Biomerica Operational KPIs
Biomerica's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $0.1M for the same period.
Data powered by FactSet, Inc. and Morningstar, Inc.
Biomerica Competitors
Biomerica competitors include Bluejay Diagnostics, Centogene, Virax Biolabs Group, NRGene, Diagonal Bio, Lifeline Biotechnologies, Ludwig Enterprises, Integragen, 2cureX and Curative Biotechnology.
Most Biomerica public comparables operate across Diagnostics & Genomics, BioTech and DeepTech.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| - | - | 0.8x | - | |||
| 0.1x | - | (0.1x) | - | |||
| (300.5x) | - | 0.7x | - | |||
| 0.6x | - | (2.0x) | - | |||
| - | - | - | - | |||
| - | - | - | - | |||
| - | - | (3.2x) | - | |||
| (0.0x) | - | 0.7x | - | |||
This data is available for Pro users. Sign up to see all Biomerica competitors and their valuation data. Start Free Trial | ||||||
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Biomerica
| When was Biomerica founded? | Biomerica was founded in 1971. |
| Where is Biomerica headquartered? | Biomerica is headquartered in United States. |
| How many employees does Biomerica have? | As of today, Biomerica has over 54 employees. |
| Is Biomerica publicly listed? | Yes, Biomerica is a public company listed on Nasdaq. |
| What is the stock symbol of Biomerica? | Biomerica trades under BMRA ticker. |
| Who are competitors of Biomerica? | Biomerica main competitors include Bluejay Diagnostics, Centogene, Virax Biolabs Group, NRGene, Diagonal Bio, Lifeline Biotechnologies, Ludwig Enterprises, Integragen, 2cureX, Curative Biotechnology. |
| What is the current market cap of Biomerica? | Biomerica's current market cap is $5M. |
| What is the current revenue of Biomerica? | Biomerica's last fiscal year revenue is $5M. |
| What is the current EV/Revenue multiple of Biomerica? | Current revenue multiple of Biomerica is 0.7x. |
| Is Biomerica profitable? | No, Biomerica is not profitable. |
| How many companies Biomerica has acquired to date? | Biomerica hasn't acquired any companies yet (or none have been disclosed publicly). |
| In how many companies Biomerica has invested to date? | Biomerica hasn't invested in any companies yet (or none have been disclosed publicly). |
See public comps similar to Biomerica
Lists including Biomerica
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.




